

Article

Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study

Carmen Marina Meseguer Barros ¹, Natalia Alzueta Isturiz ², Rita Sainz de Rozas Aparicio ³, Rafael Aguilera Vizcaíno ⁴, Laura López Esteban ^{5,†}, Sonia Anaya Ordóñez ⁶, Itxasne Lekue Alkorta ^{7,‡}, Salvadora Martín Suances ⁶, Jorge Ignacio Jiménez Arce ⁸, Maite Fernández Vicente ⁹, Yolanda Borrego Izquierdo ¹⁰, Raquel Prieto Sánchez ¹⁰, Silvia Casado Casuso ¹⁰, Rosa Madridejos ¹¹, Carmen Marquina Verde ^{9,§}, Rosa Tomás Sanz ¹¹, María Oro Fernández ¹², Sara Gallardo Borge ¹¹, Eva Lázaro López ¹³, María Belén Pina Gadea ¹⁴, Mercedes Pereira Pía ¹⁵, María Victoria Maestre Sánchez ¹⁶, Esther Ribes Murillo ¹⁷, Constanza Gómez de Oña ¹⁸, María Jesús Lallana Álvarez ¹⁴, Concepción Celaya Lecea ¹⁹, María Ana Prado Prieto ²⁰, Aranzazu Aranguez Ruiz ²¹, Vicente Olmo Quintana ²², Noemí Villén Romero ²³, Carolina Payá Giner ²⁴, Angeles Lloret Callejo ²⁵, Alvaro Fernández Ferreiro ²⁶, Blanca Basagoiti Carreño ²⁷, Ana-Aurelia Iglesias Iglesias ²⁸, Antonio Martín Alonso ^{27,||}, Ana Díez Alcántara ²⁷, Esther Marco Tejón ²⁹, Marta Lestón Vázquez ²³, M^a Ángeles Ariza Copado ³⁰, Marta Aparicio Cueva ³¹, Belén Escudero Vilaplana ¹, Marisa Nicieza ³², Gracia Picazo Sanchiz ¹, Genma María Silva Riádigos ¹, Lucía Jamart Sánchez ¹, Ángel García Álvarez ³³, Antonio García Bonilla ³⁴, Rafael Herrero Delicado ³⁵, Virginia Arroyo Pineda ³⁶, Belén de la Hija ³⁶, Amelia Troncoso Mariño ²³, Isabel Tofiño González ³⁶, Mónica Susana Mateu García ³⁷, Pablo García Vázquez ³⁸, Joaquín Pérez Martín ³⁹ and Rocío Fernández-Urrusuno ^{40,*,¶} on behalf of the Infectious Diseases SEFAP Team

Supplementary data

Table S1. Participating Spanish regions and number of patients provided to study.

Region	Patients		COVID-19 patients	
	N	%	N	%
Madrid	502	16.42	47	32.19
Catalonia	397	12.99	18	12.33
Andalucia	363	11.87	9	6.16
Basque Country	337	11.02	10	6.85
Cantabria	322	10.53	24	16.44
Asturias	282	9.22	3	2.05
Castile and Leon	228	7.46	9	6.16
Aragon	118	3.86	5	3.42
Castile La Mancha	110	3.6	8	5.48
Navarre	98	3.21	2	1.37
Galicia	66	2.16	1	0.68
Balearic Islands	58	1.90	2	1.37
Extremadura	51	1.67	1	0.68
Murcia	48	1.57	0	0.00
Canary Islands	44	1.44	5	3.42
Valencian Community	33	1.08	2	1.37
Total	3,057	100	146	100

**Table S2.** Comorbid conditions analyzed.

Respiratory chronic disease:
Chronic Obstructive Pulmonary Disease (COPD).
Cystic fibrosis.
Bronchiectasis.
Chronic bronchitis.
Emphysema.
Chronic respiratory failure.
Asthma.
Lung transplant.
Arterial hypertension.
Cardiac disease, ischaemic or hypertensive heart disease, cerebrovascular disease:
Heart failure.
Acute myocardial infarction.
Angina pectoris.
Stable coronary heart disease.
Peripheral arterial disease.
Transient ischemic attack
Stroke
Chronic neurological or mental diseases:
Dementia.
Alzheimer.
Parkinson.
Schizophrenia
Depression.
Situation that leads to immunosuppression (for an underlying illness or from therapy):
Malignancy.
Transplant.
Human immunodeficiency virus infection (VIH).
Prolonged use of corticoids
Autoimmune diseases:
Rheumatoid arthritis.
Lupus erythematosus.
Psoriasis.
Celiac disease.
Inflammatory bowel disease.
Multiple sclerosis.
Sjögren.
Other conditions
Diabetes mellitus
Chronic kidney disease.
Liver disease or failure.

Table S3. Concomitant treatments analyzed.

Proton-pump inhibitors (PPI).
Non steroidal anti-inflammatory drugs (NSAIDs).
Analgesics. Non opioids, opioids
Gabapentinoids
Antihistamines.
Cough suppressants.
Mucolytics.
Inhaled corticoids.
Systemic corticoids.
Bronchodilators.
Other systemic antiasthmatics
Antidiabetics.
Antihypertensives.
Lipid-lowering agents.
Antiplatelet drugs.
Anticoagulants.
Antidepressants.
Benzodiazepines and Z drugs.
Antipsychotics.
Other immunosuppressive agents.
Systemic antibiotics:
Antifungal drugs
Antirheumatics: hidroxicloroquine
